|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0150 AUD | 0.00% |
|
-16.67% | - |
| 05-28 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 05-27 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
| Market Cap | 7.7M 5.44M 4.7M 4.32M 4.06M 7.63M 514M 51.16M 19.92M 252M 20.43M 19.99M 872M | P/E 2024 |
-3.44x | P/E 2025 | -0.95x |
|---|---|---|---|---|---|
| Enterprise Value | 10.47M 7.4M 6.39M 5.87M 5.53M 10.38M 699M 69.57M 27.09M 343M 27.78M 27.19M 1.19B | EV / Sales 2024 |
4.09x | EV / Sales 2025 | 7.81x |
| Free-Float |
78.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/05/22 | Acrux : Application for quotation of securities - ACR | PU |
| 14/04/22 | Acrux : Application for quotation of securities - ACR | PU |
| 15/03/22 | Acrux : Application for quotation of securities - ACR | PU |
| 25/02/22 | Acrux : Updated Board Charter | PU |
| 25/02/22 | Acrux : Application for quotation of securities - ACR | PU |
| 1 week | -16.67% | ||
| Current month | +25.00% | ||
| 1 month | +50.00% | ||
| 3 months | +25.00% |
| 1 week | 0.01 | 0.02 | |
| 1 month | 0.01 | 0.02 | |
| Current year | 0.01 | 0.02 | |
| 1 year | 0.01 | 0.02 | |
| 3 years | 0.01 | 0.1 | |
| 5 years | 0.01 | 0.16 | |
| 10 years | 0.01 | 0.84 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 31/05/2025 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 20/06/2021 |
| Chief Tech/Sci/R&D Officer | - | 14/02/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Geoff Brooke
BRD | Director/Board Member | 70 | 31/05/2016 |
Ross Dobinson
CHM | Chairman | 74 | 31/12/2005 |
Timothy Oldham
BRD | Director/Board Member | - | 30/09/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | -16.67% | -21.05% | -68.09% | 5.44M | ||
| +0.24% | +1.71% | +10.73% | +82.15% | 46.28B | ||
| +2.46% | +5.97% | +51.91% | +96.77% | 34.73B | ||
| +0.35% | -2.01% | -9.52% | +34.04% | 11.56B | ||
| +1.22% | -2.85% | +12.12% | +93.88% | 11.32B | ||
| +0.57% | +3.33% | +39.31% | +130.57% | 9.27B | ||
| -0.08% | +1.20% | +13.26% | +41.20% | 7.13B | ||
| +1.22% | +1.77% | +44.21% | -17.25% | 6.6B | ||
| +0.81% | +0.44% | +29.73% | +236.35% | 6.39B | ||
| -0.63% | -3.58% | -37.81% | -7.82% | 4.98B | ||
| Average | +0.62% | -0.60% | +13.29% | +62.18% | 13.83B | |
| Weighted average by Cap. | +0.93% | +1.07% | +22.27% | +83.03% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 5.09M 3.6M 3.1M 2.85M 2.69M 5.05M 340M 33.83M 13.17M 167M 13.51M 13.22M 577M | 1.19M 841K 726K 667K 628K 1.18M 79.39M 7.91M 3.08M 38.96M 3.16M 3.09M 135M |
| Net income | -5.8M -4.1M -3.54M -3.25M -3.06M -5.75M -387M -38.54M -15M -190M -15.39M -15.06M -657M | -5.94M -4.2M -3.63M -3.33M -3.14M -5.9M -397M -39.5M -15.38M -195M -15.77M -15.44M -673M |
| Net Debt | 759K 537K 463K 426K 401K 753K 50.64M 5.04M 1.96M 24.85M 2.01M 1.97M 85.97M | 2.77M 1.96M 1.69M 1.55M 1.46M 2.75M 185M 18.42M 7.17M 90.76M 7.35M 7.2M 314M |
Employees
43
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/06/26 | 0.0150 $ | 0.00% | 984,767 |
| 17/06/26 | 0.0150 $ | -11.76% | 1,046,254 |
| 16/06/26 | 0.0170 $ | +6.25% | 1,027,700 |
| 15/06/26 | 0.0160 $ | -5.88% | 124,024 |
| 12/06/26 | 0.0170 $ | -5.56% | 2,127,316 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
Select your edition
All financial news and data tailored to specific country editions
















